Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN
These findings provide strong evidence for early intensification with apalutamide plus ADT in patients with mHSPC regardless of the disease burden.
Authors
- Kim N. Chi (ORCID: https://orcid.org/0000-0002-3782-7226)
- Joana Lencart (ORCID: https://orcid.org/0000-0001-7078-7257)
- Suneel Mundle (ORCID: https://orcid.org/0000-0003-4867-172X)
- Anders Bjartell (ORCID: https://orcid.org/0000-0002-5761-3786)
- Axel S. Merseburger (ORCID: https://orcid.org/0000-0001-6467-3931)
- Suzy Van Sanden
- Álvaro Juárez Soto (ORCID: https://orcid.org/0000-0003-4026-082X)
- Ángel Borque‐Fernando (ORCID: https://orcid.org/0000-0003-0178-4567)
- Amitabha Bhaumik
- Cristian L. Vidal-Silva (ORCID: https://orcid.org/0000-0002-1600-3447)
- Neeraj Agarwal
- Fernando Lopez-Campos
- Alejo Rodriguez-Vida
- Beatriz Garcillan
Institutions
- Johnson & Johnson (United States) (US)
- Lund University (SE)
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Skåne University Hospital (SE)
- Hospital Universitario Ramón y Cajal (ES)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.euo.2025.07.002
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04